Discriminative performance of pancreatic stone protein in predicting ICU mortality and infection severity in adult patients with infection: a systematic review and individual patient level meta-analysis.

"Declarations Competing interestsAll authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. RG has received research grants from Gebert Rüf Foundation, in addition, Dr. Graf has a patent method for assaying sepsis and outcome in humans by detection of PSP/reg licensed to LASCCO. DS reports grants from Astra-Zeneca AG, Curetis AG, Boston Scientific, other from Astra-Zeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer and Schwabe Pharma AG, Vifor AG, outside the submitted work. PE has received research grants from Abionic outside the submitted work. Ethics approval and consent to participateThe study was registered on Prospero (#CRD42022308207). The Cantonal Ethical Committee of the State of Bern (#2018-01356_V2.1_25.2.2022) reviewed and approved the meta-analysis research protocol while the respective ethical committees already approved all individual studies. Consent for publicationNot applicable. Competing interests All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. RG has received research grants from Gebert Rüf Foundation, in addition, Dr. Graf has a patent method for assaying sepsis and outcome in humans by detection of PSP/reg licensed to LASCCO. DS reports grants from Astra-Zeneca AG, Curetis AG, Boston Scientific, other from Astra-Zeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer and Schwabe Pharma AG, Vifor AG, outside the submitted work. PE has received research grants from Abionic outside the submitted work."

"Funding Open access funding provided by University of Bern. This analysis was supported by unrestricted institutional research funds to JP and YAQ."

"The study was registered on Prospero (#CRD42022308207). The Cantonal Ethical Committee of the State of Bern (#2018-01356_V2.1_25.2.2022) reviewed and approved the meta-analysis research protocol while the respective ethical committees already approved all individual studies. Declarations: Competing interestsAll authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. RG has received research grants from Gebert Rüf Foundation, in addition, Dr. Graf has a patent method for assaying sepsis and outcome in humans by detection of PSP/reg licensed to LASCCO. DS reports grants from Astra-Zeneca AG, Curetis AG, Boston Scientific, other from Astra-Zeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer and Schwabe Pharma AG, Vifor AG, outside the submitted work. PE has received research grants from Abionic outside the submitted work.: Ethics approval and consent to participateThe study was registered on Prospero (#CRD42022308207). The Cantonal Ethical Committee of the State of Bern (#2018-01356_V2.1_25.2.2022) reviewed and approved the meta-analysis research protocol while the respective ethical committees already approved all individual studies.: Consent for publicationNot applicable. Ethics approval and consent to participate: The study was registered on Prospero (#CRD42022308207). The Cantonal Ethical Committee of the State of Bern (#2018-01356_V2.1_25.2.2022) reviewed and approved the meta-analysis research protocol while the respective ethical committees already approved all individual studies."